Integral Health Asset Management LLC Purchases Shares of 300,000 Alto Neuroscience, Inc. (NYSE:ANRO)

Integral Health Asset Management LLC purchased a new stake in Alto Neuroscience, Inc. (NYSE:ANRO) during the 4th quarter, HoldingsChannel reports. The fund purchased 300,000 shares of the company’s stock, valued at approximately $1,269,000.

Several other institutional investors and hedge funds have also recently modified their holdings of ANRO. Graham Capital Management L.P. purchased a new position in shares of Alto Neuroscience during the 4th quarter valued at about $204,000. Deutsche Bank AG raised its holdings in shares of Alto Neuroscience by 31.3% during the 4th quarter. Deutsche Bank AG now owns 15,210 shares of the company’s stock valued at $64,000 after buying an additional 3,629 shares in the last quarter. Corton Capital Inc. purchased a new position in shares of Alto Neuroscience during the 4th quarter valued at about $142,000. Cantor Fitzgerald L. P. purchased a new position in shares of Alto Neuroscience during the 4th quarter valued at about $1,575,000. Finally, Bank of America Corp DE raised its holdings in shares of Alto Neuroscience by 63.7% during the 4th quarter. Bank of America Corp DE now owns 56,532 shares of the company’s stock valued at $239,000 after buying an additional 22,007 shares in the last quarter.

Analysts Set New Price Targets

A number of brokerages recently weighed in on ANRO. William Blair reissued an “outperform” rating on shares of Alto Neuroscience in a report on Friday, March 21st. HC Wainwright began coverage on Alto Neuroscience in a report on Monday, April 7th. They set a “buy” rating and a $10.00 price objective on the stock. Three investment analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $15.40.

Alto Neuroscience Trading Up 0.9%

Alto Neuroscience stock opened at $2.21 on Monday. The company has a current ratio of 13.10, a quick ratio of 13.09 and a debt-to-equity ratio of 0.05. The business’s fifty day simple moving average is $2.49 and its two-hundred day simple moving average is $3.49. Alto Neuroscience, Inc. has a 12 month low of $1.60 and a 12 month high of $17.55. The company has a market capitalization of $59.83 million, a price-to-earnings ratio of -0.87 and a beta of 1.87.

Alto Neuroscience (NYSE:ANRO) last posted its quarterly earnings results on Thursday, March 20th. The company reported ($0.56) earnings per share for the quarter, topping the consensus estimate of ($0.65) by $0.09. As a group, equities analysts predict that Alto Neuroscience, Inc. will post -2.54 earnings per share for the current fiscal year.

Alto Neuroscience Profile

Alto Neuroscience, Inc operates as a clinical-stage biopharmaceutical company in the United States. Its product pipeline comprising ALTO-100, which is in phase 2b clinical trial for the treatment of patients with major depressive disorder (MDD); and which is in phase 2a clinical trial for the treatment of post-traumatic stress disorder.